Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
As of today, Regeneron(REGN) shares are valued at $746.36. The company's market cap stands at 78.45B, with a P/E ratio of 18.02 and a dividend yield of 46.8%.
On 2025-12-17, Regeneron(REGN) stock traded between a low of $734.72 and a high of $757.35. Shares are currently priced at $746.36, which is +1.6% above the low and -1.5% below the high.
The Regeneron(REGN)'s current trading volume is 712.93K, compared to an average daily volume of 963.63K.
In the last year, Regeneron(REGN) shares hit a 52-week high of $790.98 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $790.98 and a 52-week low of $476.49.
REGN News
If you are wondering whether Regeneron Pharmaceuticals is still worth considering after its big run, or if most of the upside is already reflected in the price,...
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backe...
Analyst ratings
67%
of 30 ratingsMore REGN News
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $768 from $767 and keeps an Equal Weight rating on the shares. The fi...
HSBC raised the firm’s price target on Regeneron (REGN) to $985 from $890 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. T...